-- Pharmaron Beijing (HKG:3759, SHE:300759) recorded a 9.8% rise in attributable profit in the first quarter of 2026 to 335.4 million yuan from 305.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.
The pharmaceutical company's earnings per share rose to 0.185 yuan from 0.1733 yuan in the corresponding period of the previous fiscal year.
Revenue jumped 15% to 3.58 billion yuan from 3.1 billion yuan in the year-ago period.